AU2016238759B2 - Biotin for treating amyotrophic lateral sclerosis - Google Patents

Biotin for treating amyotrophic lateral sclerosis Download PDF

Info

Publication number
AU2016238759B2
AU2016238759B2 AU2016238759A AU2016238759A AU2016238759B2 AU 2016238759 B2 AU2016238759 B2 AU 2016238759B2 AU 2016238759 A AU2016238759 A AU 2016238759A AU 2016238759 A AU2016238759 A AU 2016238759A AU 2016238759 B2 AU2016238759 B2 AU 2016238759B2
Authority
AU
Australia
Prior art keywords
biotin
use according
medicament
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016238759A
Other languages
English (en)
Other versions
AU2016238759A1 (en
Inventor
Frédéric SEDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medday Pharmaceuticals
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016238759(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of AU2016238759A1 publication Critical patent/AU2016238759A1/en
Application granted granted Critical
Publication of AU2016238759B2 publication Critical patent/AU2016238759B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Farming Of Fish And Shellfish (AREA)
AU2016238759A 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis Ceased AU2016238759B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4 2015-03-26
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
AU2016238759A1 AU2016238759A1 (en) 2017-10-05
AU2016238759B2 true AU2016238759B2 (en) 2020-08-06

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016238759A Ceased AU2016238759B2 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Country Status (24)

Country Link
US (2) US10357480B2 (enExample)
EP (2) EP3072513A1 (enExample)
JP (1) JP6752874B2 (enExample)
KR (1) KR20170131543A (enExample)
CN (2) CN107405335A (enExample)
AU (1) AU2016238759B2 (enExample)
BR (1) BR112017020408A2 (enExample)
CA (1) CA2980660A1 (enExample)
CY (1) CY1122374T1 (enExample)
DK (1) DK3273957T3 (enExample)
EA (1) EA034394B1 (enExample)
ES (1) ES2748354T3 (enExample)
HR (1) HRP20191491T1 (enExample)
HU (1) HUE046116T2 (enExample)
IL (1) IL254619B (enExample)
LT (1) LT3273957T (enExample)
MA (1) MA41809B1 (enExample)
ME (1) ME03567B (enExample)
PL (1) PL3273957T3 (enExample)
PT (1) PT3273957T (enExample)
RS (1) RS59149B1 (enExample)
SI (1) SI3273957T1 (enExample)
SM (1) SMT201900548T1 (enExample)
WO (1) WO2016151132A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
US12458607B2 (en) * 2018-12-11 2025-11-04 Myospots Australia Pty Ltd Adhesive pad
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
US20240082296A1 (en) * 2020-10-09 2024-03-14 Tx Medic Ab Treatment of muscle atrophy using dextran sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
PL377612A1 (pl) 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2833785C (en) * 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
AU2012281042B2 (en) * 2011-07-13 2016-07-14 Cytokinetics, Inc. Combination ALS therapy
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
RS59149B1 (sr) 2019-09-30
CA2980660A1 (en) 2016-09-29
CN107405335A (zh) 2017-11-28
NZ735528A (en) 2021-09-24
US10357480B2 (en) 2019-07-23
DK3273957T3 (da) 2019-11-11
HUE046116T2 (hu) 2020-02-28
US20180125825A1 (en) 2018-05-10
SI3273957T1 (sl) 2019-11-29
PT3273957T (pt) 2019-09-18
AU2016238759A1 (en) 2017-10-05
EP3273957B1 (en) 2019-08-14
CY1122374T1 (el) 2021-01-27
KR20170131543A (ko) 2017-11-29
ES2748354T3 (es) 2020-03-16
EP3072513A1 (en) 2016-09-28
EP3273957A1 (en) 2018-01-31
IL254619A0 (en) 2017-11-30
MA41809A (fr) 2018-01-30
WO2016151132A1 (en) 2016-09-29
EA201792124A1 (ru) 2018-04-30
IL254619B (en) 2020-03-31
LT3273957T (lt) 2019-11-11
BR112017020408A2 (pt) 2018-06-05
JP2018512451A (ja) 2018-05-17
CN111973592A (zh) 2020-11-24
JP6752874B2 (ja) 2020-09-09
HRP20191491T1 (hr) 2019-11-15
EA034394B1 (ru) 2020-02-04
SMT201900548T1 (it) 2019-11-13
US20190314342A1 (en) 2019-10-17
MA41809B1 (fr) 2019-12-31
PL3273957T3 (pl) 2020-01-31
ME03567B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
US20190314342A1 (en) Method for treating demyelinating neuropathy with biotin
KR20250034521A (ko) 실조증을 치료하기 위한 릴루졸 전구약물의 용도
US9789092B2 (en) Biotin for use in treating X-linked adrenoleukodystrophy
NZ735528B2 (en) Biotin for treating demyelinating neuropathies
HK1243938B (en) Biotin for treating demyelinating neuropathies
HK1243938A1 (en) Biotin for treating demyelinating neuropathies
US8664209B2 (en) Daptomycin for multiple sclerosis
CN112641765A (zh) 丙泊酚的抗疲劳制药用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired